GPCR Prakiraan wutah bathi kanggo taun ngarep structuretx.com
The earnings growth rate model for the coming year on the GURU.Markets chart confirms the potential transition from injections to convenient pills for Structure Therapeutics (GPCR). Aggressive R&D pipeline development to create breakthrough GLP-1 molecules bolsters optimism, while -29.80 records a new level mark. The primary drivers remain the GSBR-1290 trials and a high probability of acquisition by industry behemoths, which will determine the future capitalization of Structure Therapeutics (GPCR).
GPCR (structuretx.com): rincian analitis lan laporan miturut indikator
- rega saham lan konsensus proyeksi valuasi:
- data kapitalisasi pasar:
- indikator kapitalisasi buku:
- informasi babagan utang lan solvabilitas:
Total Utang marang Modal Structure Therapeutics|GPCR - Rasio tanggungan utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Structure Therapeutics Inc.|GPCR - Gunggung kewajiban utang perusahaan|Rasio utang marang kapitalisasi buku Structure Therapeutics|GPCR - Kewajiban jangka dawa perusahaan|Utang jangka cendhak perusahaan Structure Therapeutics|Indikator likuiditas cepet structuretx.com
- data bathi resik lan rasio valuasi:
GPCR - Bathi sawise mbayar pajeg|Bathi sing dikarepake Structure Therapeutics|GPCR - Nilai perusahaan marang bathi resik|Prakiraan rega marang bathi Structure Therapeutics|GPCR - Pangali PEG|Pangali EV/EBITDA Structure Therapeutics|GPCR - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Structure Therapeutics|GPCR - Bathi saben saham sajrone patang kuartal pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan structuretx.com|GPCR - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Structure Therapeutics
Analisis wiwitan perusahaan:GPCR, Structure Pharma
To find a fundamental floor, investors must evaluate the efficiency of Structure Therapeutics (GPCR) in optimizing clinical trials and its global contractor network, which reduce regulatory costs. Analyzing the projected net profit growth rate for n+1, you can see the market consensus expectations for EPS dynamics, where an upward trend confirms margin resilience and the asset's capitalization potential amid macroeconomic stability.
Analisis perusahaan pesaing
ASND (Ascendis Pharma Inc.) - Prakiraan wutah bathi kanggo taun ngarep|Prakiraan wutah bathi kanggo taun ngarep Madrigal Corp|Prakiraan wutah bathi kanggo taun ngarep CORT|Prakiraan wutah bathi resik saben saham kanggo taun ngarep RYTM (rhythmtx.com)|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Akero AKRO|Metsera, Inc. (MTSR) - Prakiraan wutah bathi resik saben saham ing taun ngarep|MLTX - Prakiraan wutah bathi resik saben saham kanggo taun ngarep|CRNX: Prakiraan wutah bathi resik saben saham kanggo taun ngarep|NAMS: Prakiraan wutah bathi kanggo taun ngarep|SLNO - Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Amicus Therapeutics, Inc.|89bio Inc (ETNB) - Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Agios Pharmaceuticals Inc (AGIO)|Prakiraan wutah bathi saben saham kanggo taun ngarep MiMedx Corp MDXG|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Rezolute, Inc. RZLT|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep lexpharma.com (LXRX)|MBX: Prakiraan wutah bathi saben saham kanggo taun ngarep|Altimmune Inc - Proyeksi tambahing bathi saben saham ing taun ngarep|Aardvark Therapeutics Corp (AARD) - Prakiraan wutah bathi resik saben saham kanggo taun ngarep|Sagimet Biosciences Inc - Dinamika bathi saben saham sing diarepake ing taun ngarep|Prakiraan wutah bathi saben saham kanggo taun ngarep BIOA|Prakiraan wutah bathi kanggo taun ngarep biomeafusion.com|Prakiraan wutah bathi kanggo taun ngarep QNCX|Prakiraan wutah bathi saben saham kanggo taun ngarep Fractyl Health Inc. GUTS|vTv Therapeutics - Prakiraan wutah bathi saben saham kanggo taun ngarep|Proyeksi tambahing bathi saben saham ing taun ngarep ATPC (Agape ATP Corp)|PLUR: Prakiraan wutah bathi saben saham kanggo taun ngarep|SYBX - Prakiraan wutah bathi kanggo taun ngarep|Lipocine (LPCN) - Prakiraan wutah bathi resik saben saham kanggo taun ngarep|Matinas BioPharma Holdings - Dinamika bathi saben saham sing diarepake ing taun ngarep|SPRB (Spruce Biosciences, Inc.) - Prakiraan wutah bathi kanggo taun ngarep|Prakiraan wutah bathi resik saben saham ing taun ngarep Galecto Corporation GLTO|Prakiraan wutah bathi saben saham kanggo taun ngarep CTCX (Carmell Corporation)|LUMO (lumos-pharma.com) - Dinamika bathi saben saham sing diarepake ing taun ngarep|Organovo - Prakiraan wutah bathi saben saham kanggo taun ngarep|Proyeksi tambahing bathi saben saham ing taun ngarep RDUS (Radius Recycling Inc.)
